Top Markets
#1 Islamic Coin Islamic Coin +151.46%
#2 DOVU DOVU +50.33%
#3 Black Phoenix Black Phoenix +35.18%
#4 Velvet Velvet +25.69%
#5 Akedo Akedo +22.89%
#6 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +19.03%
#7 DoubleZero DoubleZero +17.26%
#8 Fake World Assets Fake World Assets +16.79%
#9 Palladium Network Palladium Network +14.94%
#10 clBTC clBTC +11.73%
Coin of the day
Islamic Coin Islamic Coin
Settings
Language
ENGLISH
Currency
USD
Theme
Bio-Path Holdings, Inc. Bio-Path Holdings, Inc.

Bio-Path Holdings, Inc.

BPTH
Rank in Stocks #39844
Bio-Path Holdings, Inc. is a U.S.-based pharmaceutical company focused on... Bio-Path Holdings, Inc. is a U.S.-based pharmaceutical company focused on developing RNAi nanoparticle drugs for oncology, with programs spanning both clinical and preclinical stages. Its innovative product development is centered around the DNAbilize platform, a drug delivery and antisense technology that employs a P-ethoxy modified deoxyribonucleic acid (DNA) backbone. This modification is specifically engineered to shield the DNA from premature degradation. The company's lead drug candidate, prexigebersen, is presently in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. Additionally, Bio-Path is advancing Liposomal Bcl-2 for refractory/relapsed lymphoma and chronic lymphocytic leukemia. Another promising asset, Liposomal STAT3, is in preclinical development, targeting pancreatic cancer, non-small cell lung cancer, and AML. Furthermore, prexigebersen-A is under development for various solid tumors. Bio-Path Holdings, Inc., founded in 2007, is headquartered in Bellaire, Texas.
Share Price
$0.035
Last synced: 2026-08-13
Market Cap
$326.98K
Change (1 day)
-12.50%
Change (1 year)
-74.55%
Country
US
Trade Bio-Path Holdings, Inc. (BPTH)

Category

Healthcare
P/E ratio for Bio-Path Holdings, Inc. (BPTH)
P/E ratio as of 2026 TTM: 0
According to Bio-Path Holdings, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Bio-Path Holdings, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.